Kidney Transplantation: The transference of a kidney from one human or animal to another.Immunoglobulins, Intravenous: Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA.Plasmapheresis: Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use.Directed Tissue Donation: Tissue, organ, or gamete donation intended for a designated recipient.Living Donors: Non-cadaveric providers of organs for transplant to related or non-related recipients.Graft Rejection: An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.Tissue Donors: Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.Graft Survival: The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.Immunosuppressive Agents: Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.Histocompatibility Testing: Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)Mesenchymal Stromal Cells: Bone-marrow-derived, non-hematopoietic cells that support HEMATOPOETIC STEM CELLS. They have also been isolated from other organs and tissues such as UMBILICAL CORD BLOOD, umbilical vein subendothelium, and WHARTON JELLY. These cells are considered to be a source of multipotent stem cells because they include subpopulations of mesenchymal stem cells.Veins: The vessels carrying blood away from the capillary beds.Varicose Veins: Enlarged and tortuous VEINS.Phlebography: Radiographic visualization or recording of a vein after the injection of contrast medium.Cord Blood Stem Cell Transplantation: Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.Cell Differentiation: Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.Mesenchymal Stem Cell Transplantation: Transfer of MESENCHYMAL STEM CELLS between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS).Fetal Blood: Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery.Busulfan: An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.Logical Observation Identifiers Names and Codes: A vocabulary database of universal identifiers for laboratory and clinical test results. Its purpose is to facilitate the exchange and pooling of results for clinical care, outcomes management, and research. It is produced by the Regenstrief Institute. (LOINC and RELMA [Internet]. Indianapolis: The Regenstrief Institute; c1995-2001 [cited 2002 Apr 2]. Available from http://www.regenstrief.org/loinc)Anemia, Aplastic: A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.Bone Marrow Transplantation: The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.Stroke Volume: The amount of BLOOD pumped out of the HEART per beat, not to be confused with cardiac output (volume/time). It is calculated as the difference between the end-diastolic volume and the end-systolic volume.Ventricular Function, Left: The hemodynamic and electrophysiological action of the left HEART VENTRICLE. Its measurement is an important aspect of the clinical evaluation of patients with heart disease to determine the effects of the disease on cardiac performance.Forced Expiratory Volume: Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity.Transplantation, Homologous: Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.Bilirubin: A bile pigment that is a degradation product of HEME.Respiratory Function Tests: Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc.Graft vs Host Disease: The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.Dictionaries, MedicalDictionaries as Topic: Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.Dictionaries, ChemicalTerminology as Topic: The terms, expressions, designations, or symbols used in a particular science, discipline, or specialized subject area.Encephalomyelitis, Autoimmune, Experimental: An experimental animal model for central nervous system demyelinating disease. Inoculation with a white matter emulsion combined with FREUND'S ADJUVANT, myelin basic protein, or purified central myelin triggers a T cell-mediated immune response directed towards central myelin. The pathologic features are similar to MULTIPLE SCLEROSIS, including perivascular and periventricular foci of inflammation and demyelination. Subpial demyelination underlying meningeal infiltrations also occurs, which is also a feature of ENCEPHALOMYELITIS, ACUTE DISSEMINATED. Passive immunization with T-cells from an afflicted animal to a normal animal also induces this condition. (From Immunol Res 1998;17(1-2):217-27; Raine CS, Textbook of Neuropathology, 2nd ed, p604-5)Encephalomyelitis: A general term indicating inflammation of the BRAIN and SPINAL CORD, often used to indicate an infectious process, but also applicable to a variety of autoimmune and toxic-metabolic conditions. There is significant overlap regarding the usage of this term and ENCEPHALITIS in the literature.Myelin Basic Protein: An abundant cytosolic protein that plays a critical role in the structure of multilamellar myelin. Myelin basic protein binds to the cytosolic sides of myelin cell membranes and causes a tight adhesion between opposing cell membranes.Internal Medicine: A medical specialty concerned with the diagnosis and treatment of diseases of the internal organ systems of adults.Rats, Inbred LewFreund's Adjuvant: An antigen solution emulsified in mineral oil. The complete form is made up of killed, dried mycobacteria, usually M. tuberculosis, suspended in the oil phase. It is effective in stimulating cell-mediated immunity (IMMUNITY, CELLULAR) and potentiates the production of certain IMMUNOGLOBULINS in some animals. The incomplete form does not contain mycobacteria.Encephalomyelitis, Acute Disseminated: An acute or subacute inflammatory process of the CENTRAL NERVOUS SYSTEM characterized histologically by multiple foci of perivascular demyelination. Symptom onset usually occurs several days after an acute viral infection or immunization, but it may coincide with the onset of infection or rarely no antecedent event can be identified. Clinical manifestations include CONFUSION, somnolence, FEVER, nuchal rigidity, and involuntary movements. The illness may progress to COMA and eventually be fatal. (Adams et al., Principles of Neurology, 6th ed, p921)Myelin-Oligodendrocyte Glycoprotein: A transmembrane protein present in the MYELIN SHEATH of the CENTRAL NERVOUS SYSTEM. It is one of the main autoantigens implicated in the pathogenesis of MULTIPLE SCLEROSIS.Myelin Proteolipid Protein: A myelin protein that is the major component of the organic solvent extractable lipoprotein complexes of whole brain. It has been the subject of much study because of its unusual physical properties. It remains soluble in chloroform even after essentially all of its bound lipids have been removed. (From Siegel et al., Basic Neurochemistry, 4th ed, p122)Myelin-Associated Glycoprotein: A myelin protein found in the periaxonal membrane of both the central and peripheral nervous systems myelin sheaths. It binds to cells surface receptors found on AXONS and may regulate cellular interactions between MYELIN and AXONS.Cytochrome-c Oxidase Deficiency: A disease that results from a congenital defect in ELECTRON TRANSPORT COMPLEX IV. Defects in ELECTRON TRANSPORT COMPLEX IV can be caused by mutations in the SURF1, SCO2, COX10, or SCO1 genes. ELECTRON TRANSPORT COMPLEX IV deficiency caused by mutation in SURF1 manifests itself as LEIGH DISEASE; that caused by mutation in SCO2 as fatal infantile cardioencephalomyopathy; that caused by mutation in COX10 as tubulopathy and leukodystrophy; and that caused by mutation in SCO1 as early-onset hepatic failure and neurologic disorder. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/Omim, MIM#220110, May 17, 2001)Acyl-CoA Oxidase: An enzyme that catalyzes the first and rate-determining steps of peroxisomal beta-oxidation of fatty acids. It acts on COENZYME A derivatives of fatty acids with chain lengths from 8 to 18, using FLAVIN-ADENINE DINUCLEOTIDE as a cofactor.Rare Diseases: A large group of diseases which are characterized by a low prevalence in the population. They frequently are associated with problems in diagnosis and treatment.Microbodies: Electron-dense cytoplasmic particles bounded by a single membrane, such as PEROXISOMES; GLYOXYSOMES; and glycosomes.Oxidoreductases: The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9)Leigh Disease: A group of metabolic disorders primarily of infancy characterized by the subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, dysphagia, and lactic acidosis. Pathological features include spongy degeneration of the neuropile of the basal ganglia, thalamus, brain stem, and spinal cord. Patterns of inheritance include X-linked recessive, autosomal recessive, and mitochondrial. Leigh disease has been associated with mutations in genes for the PYRUVATE DEHYDROGENASE COMPLEX; CYTOCHROME-C OXIDASE; ATP synthase subunit 6; and subunits of mitochondrial complex I. (From Menkes, Textbook of Child Neurology, 5th ed, p850).Orphan Drug Production: Production of drugs or biologicals which are unlikely to be manufactured by private industry unless special incentives are provided by others.Peroxisomal Disorders: A heterogeneous group of inherited metabolic disorders marked by absent or dysfunctional PEROXISOMES. Peroxisomal enzymatic abnormalities may be single or multiple. Biosynthetic peroxisomal pathways are compromised, including the ability to synthesize ether lipids and to oxidize long-chain fatty acid precursors. Diseases in this category include ZELLWEGER SYNDROME; INFANTILE REFSUM DISEASE; rhizomelic chondrodysplasia (CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC); hyperpipecolic acidemia; neonatal adrenoleukodystrophy; and ADRENOLEUKODYSTROPHY (X-linked). Neurologic dysfunction is a prominent feature of most peroxisomal disorders.Hypertelorism: Abnormal increase in the interorbital distance due to overdevelopment of the lesser wings of the sphenoid.Sulfite Oxidase: A MOLYBDENUM requiring enzyme that catalyzes the terminal reaction in the oxidative degradation of SULFUR AMINO ACIDS with the formation of a sulfate. A deficiency of sulfite oxidase results in sulfocysteinuria.Fetal Hemoglobin: The major component of hemoglobin in the fetus. This HEMOGLOBIN has two alpha and two gamma polypeptide subunits in comparison to normal adult hemoglobin, which has two alpha and two beta polypeptide subunits. Fetal hemoglobin concentrations can be elevated (usually above 0.5%) in children and adults affected by LEUKEMIA and several types of ANEMIA.Pancytopenia: Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.Bone Marrow DiseasesAnemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.Erythropoiesis: The production of red blood cells (ERYTHROCYTES). In humans, erythrocytes are produced by the YOLK SAC in the first trimester; by the liver in the second trimester; by the BONE MARROW in the third trimester and after birth. In normal individuals, the erythrocyte count in the peripheral blood remains relatively constant implying a balance between the rate of erythrocyte production and rate of destruction.Anemia, Macrocytic: Anemia characterized by larger than normal erythrocytes, increased mean corpuscular volume (MCV) and increased mean corpuscular hemoglobin (MCH).Bone Marrow: The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.Anemia, Sickle Cell: A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.Hemoglobins: The oxygen-carrying proteins of ERYTHROCYTES. They are found in all vertebrates and some invertebrates. The number of globin subunits in the hemoglobin quaternary structure differs between species. Structures range from monomeric to a variety of multimeric arrangements.Herpesvirus 4, Human: The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies.Antilymphocyte Serum: Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.Antigens, Viral: Substances elaborated by viruses that have antigenic activity.Idoxuridine: An analog of DEOXYURIDINE that inhibits viral DNA synthesis. The drug is used as an antiviral agent.Epstein-Barr Virus Nuclear Antigens: Nuclear antigens encoded by VIRAL GENES found in HUMAN HERPESVIRUS 4. At least six nuclear antigens have been identified.Epstein-Barr Virus Infections: Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).Burkitt Lymphoma: A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.Cell Count: The number of CELLS of a specific kind, usually measured per unit volume or area of sample.Superinfection: A frequent complication of drug therapy for microbial infection. It may result from opportunistic colonization following immunosuppression by the primary pathogen and can be influenced by the time interval between infections, microbial physiology, or host resistance. Experimental challenge and in vitro models are sometimes used in virulence and infectivity studies.Cell Line: Established cell cultures that have the potential to propagate indefinitely.Organ Transplantation: Transference of an organ between individuals of the same species or between individuals of different species.Liver Transplantation: The transference of a part of or an entire liver from one human or animal to another.Chimerism: The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with MOSAICISM in which the different cell populations are derived from a single individual.Heart Transplantation: The transference of a heart from one human or animal to another.Transplantation Immunology: A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection.Transplantation: Transference of a tissue or organ from either an alive or deceased donor, within an individual, between individuals of the same species, or between individuals of different species.

Immunological control of a murine gammaherpesvirus independent of CD8+ T cells. (1/1079)

Adult thymectomized C57 BL/6J mice were depleted of T cell subsets by MAb treatment either prior to, or after, respiratory challenge with murine gammaherpesvirus-68. Protection against acute infection was maintained when either the CD4+ or the CD8+ T cell population was greatly diminished, whereas the concurrent removal of both T cell subsets proved invariably fatal. The same depletions had little effect on mice with established infection. The results indicate firstly that both CD4+ and CD8+ T cells play a significant part in dealing with the acute infection, and secondly that virus-specific antibody contributes to controlling persistent infection with this gammaherpesvirus.  (+info)

Long-term results of pancreas transplantation under tacrolius immunosuppression. (2/1079)

BACKGROUND: The long-term safety and efficacy of tacrolimus in pancreas transplantation has not yet been demonstrated. The observation of prolonged pancreatic graft function under tacrolimus would indicate that any potential islet toxicity is short-lived and clinically insignificant. We report herein the results of pancreas transplantation in patients receiving primary tacrolimus immunosuppression for a minimum of 2 years. METHODS: From July 4, 1994 until April 18, 1996, 60 patients received either simultaneous pancreas-kidney transplant (n=55), pancreas transplant only (n=4), or pancreas after kidney transplantation (n=1). Baseline immunosuppression consisted of tacrolimus and steroids without antilymphocyte induction. Azathioprine was used as a third agent in 51 patients and mycophenolate mofetil in 9. Rejection episodes within the first 6 months occurred in 48 (80%) patients and were treated with high-dose corticosteroids. Antilymphocyte antibody was required in eight (13%) patients with steroid-resistant rejection. RESULTS: With a mean follow-up of 35.1+/-5.9 months (range: 24.3-45.7 months), 6-month and 1-, 2-, and 33-year graft survival is 88%, 82%, 80%, and 80% (pancreas) and 98%, 96%, 93%, and 91% (kidney), respectively. Six-month and 1-, 2-, and 3-year patient survival is 100%, 98%, 98%, and 96.5%. Mean fasting glucose is 91.6+/-13.8 mg/dl, and mean glycosylated hemoglobin is 5.1+/-0.7% (normal range: 4.3-6.1%). Mean tacrolimus dose is 6.5+/-2.6 mg/day and mean prednisone dose 2.0+/-2.9 mg/day at follow-up. Complete steroid withdrawal was possible in 31 (65%) of the 48 patients with functioning pancreases. CONCLUSIONS: These data show for the first time that tacrolimus is a safe and effective long-term primary agent in pancreas transplantation and provides excellent long-term islet function without evidence of toxicity while permitting steroid withdrawal in the majority of patients.  (+info)

Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. (3/1079)

We report the results of the first prospective randomized multicenter study of immunosuppressive treatment in patients with previously untreated nonsevere aplastic anemia (AA) as defined by a neutrophil count of at least 0.5 x 10(9)/L and transfusion dependence. Patients were randomized to receive cyclosporin (CSA) alone or the combination of horse antithymocyte globulin ([ATG] Lymphoglobuline; Merieux, Lyon, France) and CSA. The endpoint of the study was the hematologic response at 6 months. One hundred fifteen patients were randomized and assessable with a median follow-up period of 36 months; 61 received CSA and 54 ATG and CSA. In the CSA group, the percentage of complete and partial responders was 23% and 23%, respectively, for an overall response rate of 46%. A significantly higher overall response rate of 74% was found in the ATG and CSA group, with 57% complete and 17% partial responders (P =. 02). Compared with CSA alone, the combination of ATG and CSA resulted in a significantly higher median hemoglobin level and platelet count at 6 months. Fewer patients required a second course of treatment before 6 months due to a nonresponse. In the CSA group, 15 of 61 (25%) patients required a course of ATG before 6 months because of disease progression, compared with only 3 of 54 (6%) in the ATG and CSA group. The survival probabilities for the two groups were comparable, 93% (CSA group) and 91% (ATG and CSA group), but at 180 days, the prevalence of patients surviving free of transfusions, which excluded patients requiring second treatment because of nonresponse, death, disease progression, or relapse, was 67% in the CSA group and 90% in the ATG and CSA group (P =.001). We conclude that the combination of ATG and CSA is superior to CSA alone in terms of the hematologic response, the quality of response, and early mortality, and a second course of immunosuppression is less frequently required.  (+info)

Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. (4/1079)

To determine whether the antigen-driven T-cell response is involved in the pathogenesis of aplastic anemia (AA), we examined the complementarity-determining region 3 (CDR3) size distribution of T-cell receptor (TCR) beta-chain (BV) subfamilies in the bone marrow (BM) of untreated AA patients. AA patients who did not respond to immunosuppressive therapy and those who obtained unmaintained remission early after cyclosporine (CyA) or antithymocyte globulin (ATG) therapy exhibited essentially a normal CDR3 size pattern. In contrast, five patients who needed continuous administration of CyA to maintain remission exhibited a skewed CDR3 size pattern in a number (>40%) of BV subfamilies suggestive of clonal predominance. The skewing of CDR3 size distribution became less pronounced in one of the CyA-dependent patients when the patient achieved unmaintained remission after a 4-year therapy with CyA, whereas it persisted longer than 7 years in the other patient requiring maintenance therapy. Sequencing of BV15 cDNA for which the CDR3 size pattern exhibited apparent clonal predominance in all CyA-dependent patients showed high homology of the amino acid sequence of the CDR3 between two different patients. These findings indicate that antigen-driven expansion of T cells is involved in the pathogenesis of AA characterized by CyA-dependent recovery of hematopoiesis.  (+info)

Late graft failure 8 years after first bone marrow transplantation for severe acquired aplastic anemia. (5/1079)

A 14-year-old patient with acquired very severe aplastic anemia (VSAA) underwent bone marrow transplantation (BMT) from his HLA-identical brother. Preparative therapy was cyclophosphamide (CY) 200 mg/kg over 4 days. GVHD prophylaxis was with cyclosporin A (CsA) for a year. After an 8 year follow-up during which the patient was well with normal blood counts, graft failure occurred. At this time marrow chimerism studies demonstrated that 85% of hemopoiesis was of recipient origin. The patient was re-engrafted from the same donor after conditioning with CY 200 mg/kg over 4 days plus rabbit antithymocyte globulin (ATG) 3.5 mg/kg/day for 3 days. After 140 days follow-up he has a normal blood count. The possible causes of the graft failure are discussed. This case demonstrates that, although rarely, very late graft failure may occur after BMT for AA and highlights the need for long-term monitoring even in apparently successfully transplanted patients.  (+info)

Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. (6/1079)

The present study was undertaken to acquire a rationale for clinical dose adjustment of anti-thymocyte globulin (ATG) to improve cost effectiveness and safety of graft-versus-host disease prophylaxis. The concentration of rabbit ATG in the serum of 12 patients was measured by ELISA and by the inhibitory effect on phytohaemagglutinin-induced blastogenesis. At 10 mg/ml ATG, 3H-thymidine incorporation was effectively blocked. Serial two-fold dilution of ATG showed that this effect decreased in a concentration-dependent manner and was lost at 10 ng/ml ATG. One hundred microlitres serum taken at day -1 to +22 post transplant effected significant inhibition of the phytohaemagglutinin-response with 49+/-12% c.p.m. (x +/- s.d.) on day +1 post transplant compared to 93+/-13% c.p.m. on day -1 (P<0.001, unpaired one-sided t-test). The rabbit-IgG was maximal at a concentration of 907+/-187 microl/ml at day 0. Subsequently, it decreased with time. While rabbit-IgG was detectable for a long period (e.g. 160 microg/ml at day +22 in patient MD), the effect on the phytohaemagglutinin-response of normal mononuclear cells lasted up to 4 days post transplant. We conclude that 90 mg/kg body weight ATG-Fresenius given prior to marrow transplant leads to sustained T cell immunosuppression post transplant.  (+info)

Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow. (7/1079)

A five-agent GVHD prophylaxis programme consisting of cyclosporin A, methotrexate, anti-thymocyte-globulin, pentaglobin and metronidazol was given to 48 recipients of unrelated donor marrow with chronic myelogenous leukemia, acute leukemia, myelodysplastic syndromes, and familiar lymphocytic hemophagocytosis of an average age of 33.5 (0.6-56) years. GVHD grades II-IV occurred in 18 patients (39%) and grades III-IV in five patients (11%). Chronic GVHD developed in nine patients (23%), three limited and six extensive. Fifteen patients died. Clinical relapse was detected in eight patients. Four patients died as a consequence of the underlying disease and subsequent treatment, 11 patients died of transplant-related causes. After a median follow-up of 19 months, the overall and disease-free survival are 67% and 62%, respectively. Survival by age is as follows: 0-19 years: 12/13 patients; 20-39 years: 14/25 patients; 40-59 years: 7/10 patients. The five-agent GVHD prophylaxis regimen is effective. Matched-unrelated donor transplants can be carried out safely in patients younger than 50 years of age. The results in patients younger than 20 years of age should encourage matched-unrelated donor transplants at earlier stages of the disease.  (+info)

L-Arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. (8/1079)

BACKGROUND: Mesangial cell lysis in the antithymocyte serum (ATS)-induced model of glomerulonephritis is dependent on the generation of cytotoxic nitric oxide (NO) through transient induction of NO synthase (iNOS). We hypothesized that increased availability of L-arginine (L-Arg) during mesangial cell lysis might provide iNOS with increased substrate leading to increased lysis, and that this increased lysis would be reflected in more severe fibrotic disease at day 6. METHODS: To ensure whole body equilibration with high L-Arg at the time of injury, rats were pretreated with 1% L-Arg in drinking water for one week prior to the administration of ATS. Animals were sacrificed six hours after ATS injection when previous experiments had indicated iNOS induction had occurred and at six days. At six hours, plasma was obtained for L-Arg levels and nitrite/nitrate (NOx) content. Renal tissues were taken for histological evaluation of glomerular cell counts, macrophage infiltration (ED-1), and iNOS expression. Glomeruli were isolated for detection of iNOS mRNA and placed in culture to study the dependence of NO production on L-Arg concentration. In rats sacrificed at six days, L-Arg supplementation was stopped 16 hours after ATS injection. Fibrotic disease was evaluated by urinary protein excretion, histological assessment of glomerular cell number, matrix accumulation, and production of transforming growth factor-beta1 and matrix components fibronectin and plasminogen activator inhibitor type-1 (PAI-1) by isolated glomeruli in culture. RESULTS: At six hours, the glomerular cell number was significantly reduced by ATS injection (P < 0.01) and further significantly (P < 0. 05) reduced by L-Arg feeding [normal control (NC) = 64.2 +/- 1, ATS = 53.4 +/- 0.7, ATS + L-Arg = 50.8 +/- 0.7]. Disease increased macrophage infiltration and iNOS protein and iNOS mRNA levels markedly (P < 0.01), whereas L-Arg feeding did not further increase these variables. Plasma L-Arg levels (nmol/ml) were reduced by disease (NC = 121 +/- 9, ATS = 84 +/- 13, P < 0.01) and elevated by L-Arg feeding (ATS + L-Arg = 166 +/- 12, P < 0.01). Plasma NOx was significantly increased by ATS and further increased by ATS + L-Arg (P < 0.05). Production of NOx by cultured glomeruli showed striking L-Arg concentration dependence in six hours but not in normal glomeruli. In the group sacrificed at day 6, day 2 proteinuria was higher in the ATS + L-Arg group compared with the ATS alone group (P < 0.05). Measures of fibrotic disease at day 6 all showed large increases over control with ATS alone (P < 0.01), and further small, but significant increases when L-Arg was combined with ATS (P < 0.05). CONCLUSIONS: The results indicate that if given during disease induction, L-Arg supplementation can enhance iNOS-dependent tissue injury by providing increased substrate. Although the increase in injury with L-Arg supplementation was small, it led to increased fibrosis at day 6. These data predict that in diseases with repeated iNOS-dependent tissue injury, L-Arg supplementation may produce cumulative increases in tissue fibrosis.  (+info)

*Michael Woodruff

Among these contributions, Woodruff's work with anti-lymphocyte serum has led to its wide use to reduce rejection symptoms in ... Woodruff also commenced work on antilymphocyte serum for immunosuppression, with little initial success. While in Aberdeen, ...

*Medical Research Club

Peter Medawar gave a lecture entitled "Anti-lymphocyte serum" in May 1967; Henry Harris discussed "The expression of genetic ...

*Thymoglobulin

Since the discovery of a link between antilymphocyte serum (ALS) and lymphocyte depletion by Metchnikoff in 1899, various ... leading to testing of ATG derived from rabbit serum. Thymoglobulin was the first commercial rabbit-derived ATG to be introduced ... was originally developed as one of various tested preparations of antilymphocyte globulin (ALG) specifically generated against ...

*List of MeSH codes (D12.776)

... immune sera MeSH D12.776.377.715.548.114.573.203 - antilymphocyte serum MeSH D12.776.377.715.548.114.580 - immunoconjugates ...

*List of MeSH codes (D12.776.124)

... immune sera MeSH D12.776.124.486.485.114.573.203 -- antilymphocyte serum MeSH D12.776.124.486.485.114.573.601 -- antitoxins ... immune sera MeSH D12.776.124.790.651.114.573.203 -- antilymphocyte serum MeSH D12.776.124.790.651.114.580 -- immunoconjugates ...

*List of MeSH codes (A12)

... serum MeSH A12.207.152.846.500 --- immune sera MeSH A12.207.152.846.500.203 --- antilymphocyte serum MeSH A12.207.180 --- body ...

*List of MeSH codes (D20)

... immune sera MeSH D20.215.401.203 --- antilymphocyte serum MeSH D20.215.535 --- menotropins MeSH D20.215.659 --- picibanil MeSH ...

*Anti-lymphocyte globulin

... (ALG) is an infusion of animal- antibodies against human T cells which is used in the treatment of ... The product was manufactured by Upjohn and Merieux, as well as the Schweizerisches Serum- und Impfinstitut in Bern, the latter ... "Guillain Barré syndrome precipitated by the use of antilymphocyte globulin in the treatment of severe aplastic anaemia". J. ... Treatment of aplastic anaemia by antilymphocyte glubulin with and without allogeneic bone marrow infusions, in Lancet (1977) 2: ...

*Immunosuppressive drug

Later during the treatment, some patients develop serum sickness or immune complex glomerulonephritis. Serum sickness arises ... The antilymphocyte (ALG) and antithymocyte antigens (ATG) are being used. They are part of the steroid-resistant acute ... As of March 2005, there are two preparations available to the market: Atgam, obtained from horse serum, and Thymoglobuline, ... It is possible to diminish their toxicity by using highly purified serum fractions and intravenous administration in the ...

*Anti-thymocyte globulin

When he subsequently collected serum from these Guinea pigs and injected it into normal mice he observed a marked depletion in ... A similar trial of anti-lymphocyte globulin showed a trend in reduction of aGVH that was not statistically significant, but a ...

*Intestine transplantation

Additionally, blood serum should be tested for the presence of viruses, including HIV, hepatitis B and C, cytomegalovirus (CMV ... They may also be treated with anti-lymphocyte antibodies (anti-thymocyte globulin, alemtuzumab), irradiation directed against ... and serum pH and lactate levels measured for evidence of intestinal ischemia. The patient's immune system is strongly modulated ...

*Aplastic anemia

Corticosteroids are generally ineffective,[citation needed] though they are used to ameliorate serum sickness caused by ATG. ... First line treatment for aplastic anemia consists of immunosuppressive drugs, typically either anti-lymphocyte globulin or anti ... cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte ...

*Campesterol

Serum levels of campesterol and the ratio of campesterol to cholesterol have been proposed as measures of cardiac risk. Some ... "Immunological and rheological parallels in patients with autoimmune thrombocytopenic purpura treated with antilymphocyte ... Study results of serum levels have been conflicting. A recent meta-analysis suggests that no clear relationship exists, and ... "Response of Serum Lipids and Lipoproteins of Man to Beta-Sitosterol and Safflower Oil". Circulation. 17 (5): 890-9. doi:10.1161 ...
Lappe, M A. and Blair, P B., "Interference with mammary tumorigenesis by antilymphocyte serum. Abstr." (1970). Subject Strain Bibliography 1970. 1374 ...
Epstein-Barr virus (EBV) associated lymphoproliferative disorder (LPD) after immunosuppressive therapy for aplastic anemia (AA) is extremely rare in a nontransplant setting and has not been well described. This report describes a severe AA patient in whom fatal EBV-LPD developed after being treated with rabbit antithymocyte globulins (ATG) and cyclosporine A (CsA). An 81-year-old man was diagnosed as having severe AA. He was started on CsA followed by administration of ATG for five consecutive days. One month after the start of ATG, persistent fever which was not responsive to antibiotics or antifungal agents developed and atypical lymphocytes emerged in peripheral blood. Repeated blood cultures were negative. An extremely high level of EBV virus in his peripheral blood plasma was detected by means of a quantitative real-time PCR assay. Even after the cessation of CsA, the fever persisted and the peripheral atypical lymphocytes proliferated rapidly. The patient suffered from respiratory failure, liver
Anti-lymphocyte globulin (ALG) is an infusion of animal- antibodies against human T cells which is used in the treatment of acute rejection in organ transplantation. Its use was first reported by Thomas Starzl in 1966. Its use in transplant was supplanted by thymoglobulin between 1984 and 1999. It has also been used in the treatment of aplastic anemia. It is less commonly used than the similar anti-thymocyte globulin (ATG), and like ATG it is associated with cytokine release syndrome in the short term and an increased risk of post-transplant lymphoproliferative disorder in the long term. ALG is more likely to cause side effects than ATG, but is safer than OKT3. The product was manufactured by Upjohn and Merieux, as well as the Schweizerisches Serum- und Impfinstitut in Bern, the latter of which was made by injecting horses with human thoracic duct lymphocytes and was called "Lymphoser Berna". Hakim, Nadey; Danovitch, Gabriel (2013). Transplantation Surgery. Springer Science & Business Media. p. ...
antilymphocyte globulin, ALS, ALG) an antiserum, containing antibodies that suppress lymphocytic activity, prepared by injecting an animal with lymphocytes. ALS may be given to a patient to prevent the immune reaction that causes tissue rejection following transplantation of such organs as kidneys or of bone marrow. Administration naturally also impairs other immunity mechanisms, making infection a serious hazard. ...
Definition of antithymocyte globulin in the Financial Dictionary - by Free online English dictionary and encyclopedia. What is antithymocyte globulin? Meaning of antithymocyte globulin as a finance term. What does antithymocyte globulin mean in finance?
Carcinogenesis:, Hereditary Factors:, Neoplasm:, Serology: Antigen,, Transplantation:, Types of Tumors:, Transplantable Tumors: H 2712, Genes: H-1 - Histocompatibility-1, H-2 - Histocompatibility-2, Strains: CBA, C3H/HE, C57BL/6. ...
This trial will compare the efficacy and tolerability of antithymocyte globulin and interleukin-2 receptor antagonists (basliximab or daclizumab) as induction
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
The Swedish researchers have published their procedure for transplanting a uterus.4 Acute pharmacotherapy is required during the surgery, and long-term immunosuppressive pharmacotherapy is necessary to maintain the viability of the transplanted uterus.. Before the transplant, recipients received mycophenolate mofetil 1 g, and both recipients and donors received piperacillin-tazobactam 4 g.4 To initiate immunosuppression, patients were given methylprednisolone 500 mg. To deplete T lymphocytes, patients also received two IV injections of antithymocyte globulin antibodies (either rabbit antithymocyte globulin 2.5 mg/kg or equine antithymocyte globulin 5 mg/kg) 12 hours apart.4. The anesthesia used in donors and recipients during their respective procedures was similar. A mixture of bupivacaine 10 mg and morphine 0.1 mg was given intrathecally at the L3-4 or L4-5 level. Anesthesia was induced with an infusion of remifentanil 0.25 mg/kg/min IV and a propofol bolus (2-3 mg/kg), which was followed with ...
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patients immune system from rejecting the donors stem cells. The donated stem cells may replace the patients immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the bodys normal cells. Giving tacrolimus, sirolimus, antithymocyte globulin, and methotrexate before and after transplant may stop this from happening.. PURPOSE: This phase II trial is studying how well sirolimus, tacrolimus, and antithymocyte globulin work in preventing graft-versus-host disease in patients undergoing a donor stem cell transplant for hematological cancer . ...
A patient with Sézary syndrome developed a diffuse undifferentiated lymphoma of T-cell origin. After becoming resistant to multiple chemotherapeutic agents, the patient was treated with antithymocyte globulin. A 75% reduction in adenopathy and complete resolution of skin erythema was observed during an 8-day period. In addition the percent of circulating T cells and the ability of those cells to respond to phytohemagglutinin and concanavalin A were reduced after antithymocyte globulin therapy. The patient died of an intracerebral hemorrhage secondary to profound thrombocytopenia. The study suggests that tumor lysis may be achieved by passive antibody therapy in certain advanced lymphomas. ...
View the review history for Modest dose anti-thymocyte globulin administered intraoperatively is safe and effective in kidney transplantations: a retrospective study
Easy to read patient leaflet for anti-thymocyte globulin (equine). Includes indications, proper use, special instructions, precautions, and possible side effects.
Starzl, Thomas E and Marchioro, Thomas L and Faris, Tanous D and McCardle, Robert J and Iwaski, Yoji (1966) Avenues of future research in homotransplantation of the liver with particular reference to hepatic supportive procedures, antilymphocyte serum, and tissue typing. The American Journal of Surgery, 112 (3). 391 - 400. ISSN 0002-9610 ...
The pathogenesis of type 1 diabetes in both humans and NOD mice appears dependent upon an aberrant immune response that results in the destruction of insulin-producing β-cells. While prevention of type 1 diabetes in NOD mice can be accomplished through a wide variety of monotherapies, reversal of overt disease has considerably fewer reported efficacious therapies (30,31). Of those that do show success, many combine two or more therapeutic agents to achieve this reversal (32,33). Indeed, one of the earliest demonstrations for the ability of combination therapy to reverse hyperglycemia in NOD mice utilized a somewhat similar form of murine ATG, anti-lymphocyte serum, in combination with exendin-4, to effectively reverse disease in this animal model of type 1 diabetes (14). Consequently, herein we have described an approach using two clinically relevant therapies, ATG and GCSF, for the purpose of immunomodulation that would provide benefit in terms of reversing type 1 diabetes, as demonstrated in ...
Introduction: ATG-Fresenius, a highly purified rabbit polyclonal anti-human T-lymphocyte immunoglobulin resulting from immunisation of rabbits with the Jurkat T-Lymphoblast cell line is currently used for the prevention of acute rejection in patients receiving solid organ-transplants. The aim of this study was to investigate the in vitro activity of ATG-Fresenius that underlies its activity in prevention of ischemia-reperfusion injury in solid organ transplantation.. Material and methods: Human vascular endothelial cells (HUVEC) and peripheral blood mononuclear cells (PBMCs) were isolated from umbilical vein or peripheral blood, incubated 20 to 24 h before analysis of adhesion molecule expression and use in the ATG Fresenius-binding or immune cell adhesion assays. The cells were cultured alone or activated with TNF-alpha (HUVECs) or phytohaemagglutinin (PBMCs) for 20 h. HUVEC were incubated for 30 min at 2-8 C with 10 and 100 mg/mL ATG-Fresenius (Fresenius Biotech GmbH) or reference rabbit IgG ...
Larsen JT, Hogan WJ, Micallef IN, Dispenzieri A, Gertz MA, Inwards DJ, Tun HW, Roy V, Geyer SM, Allred JB, Wu W, Ansell SM, Elliott MA, Tefferi A, Porrata LF, Gastineau DA, Lacy MQ, Litzow MR. A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin. Leuk Lymphoma. 2013 Aug; 54(8):1713-8. Epub 2012 Dec 31 ...
The aim of our study was to compare the different GvHD prophylaxis in the non-TCD Haplo-SCT setting. In a homogenous population of AML in CR, we showed that the use of PTCY for GvHD prophylaxis was associated with better LFS and GRFS, similar relapse and cGvHD, less NRM and less severe aGvHD, than in the ATG group.. The incidence of grade 3-4 aGvHD in both groups is consistent with the previous reports in this setting. The largest study from Huang et al. reported a 10%-14% incidence of severe aGvHD in patients receiving ATG-based GvHD prophylaxis.6,7 Other groups reported an incidence of grade 3-4 aGvHD ranging from 9±3% to 22±8% using the association of ATG with CSA, MTX plus MMF and basiliximab8,25 or sirolimus and MMF26 as GvHD prophylaxis.. The PTCY regimen was first introduced by Luznik et al.9,27 using PTCY with tacrolimus and MMF, BM graft and RIC conditioning, with a low 5% incidence of grade 3-4 aGvHD. This platform was rapidly adopted by other centers with similar results. Bacigalupo ...
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant using stem cells that closely match the patients stem cells, helps stop
Physician reviewed lymphocyte immune globulin, anti-thymocyte (equine) patient information - includes lymphocyte immune globulin, anti-thymocyte description, dosage and directions.
ESN individuals also display some unconventional humoral immune responses that may play a role in HIV neutralization: a very effective protective mechanism against viral infections. Two kinds of HIV-related humoral immune responses have been described in ESN individuals so far: antibodies to cellular proteins involved in the HIV infection/entry process, and HIV-specific mucosal antibodies.. The induction of anticell immune responses is rather common, and antilymphocyte antibodies have been observed early in sera from HIV-infected patients [55-57]. As the majority of these antibodies recognize HLA or CD4 molecules, their appearance had first been attributed to the cytopathic effect of HIV infection or to the long-lasting exposure to blood derivatives, as in the case of haemophiliacs [58,59]. In this regard, HIV-blocking IgG directed against HLA class I and CD4 molecules have been found in sera of ESN individuals [60-63] (n = 14/31). Anti-CD4 antibodies of ESN individuals recognize epitopes ...
RATIONALE: Giving chemotherapy before a donor bone marrow stem cell transplant helps stop the growth of cancer cells. Chemotherapy and antithymocyte glo
Find the Blink Price & Information for Thymoglobulin - as low as $23,644.91 - pick up at your pharmacy (Rite Aid, Walmart & more). Price transparency and up to 80% savings.
A lightweight gel that strengthens skin, repairs aging skin, and protects against future signs of aging. Formulated for all skin types.
This is what I understand is happening with my white blood cells, especially T-Cells. T-Cells are the dudes that really go out to destroy foreign particles in the body. We have to get them down in order for them not to attack incoming stem cells wednesday. over the past 4 days, the busulfex has essentially put the whammy on new T-Cell production. IE: there are no re-enforcements for the T-Cells. However, the busulfex only stops new production of T-Cells, therefore any T-Cells hanging around before the busulfex must be now nuked. So they use this stuff called ATG. This are Antithymocyte Globulin Rabbit antibodies. Harmless little rabbit antibodies. However, when they are injected into the patients system, they alarm the T-Cells to the max. This is what the T-Cells do: Eat the antibodies, release cytokines, hope for re-enforcements. Eating the antibodies is good. Dont need them, but they are really not a harm anyway. Releasing Cytokines will heat things up causing fever, sometimes killing the ...
Select Interest category. Page reloads and displays only events associated with that Interest. A link, All, followed by , will display before this select. ...
Looking for online definition of antithymocyte globulin in the Medical Dictionary? antithymocyte globulin explanation free. What is antithymocyte globulin? Meaning of antithymocyte globulin medical term. What does antithymocyte globulin mean?
We evaluated the role of granulocyte colony-stimulating factor (G-CSF) in patients with severe aplastic anemia (SAA) treated with antithymocyte globulin (ATG) and cyclosporine (CSA). Between January 2002 and July 2008, 192 patients with newly diagnosed SAA not eligible for transplantation were entered into this multicenter, randomized study to receive ATG/CSA with or without G-CSF. Overall survival (OS) at 6 years was 76% ± 4%, and event-free survival (EFS) was 42% ± 4%. No difference in OS/EFS was seen
Before treatment, allergy to ATG was determined by intradermal injection of 0.1 mL of ATG at a concentration of 5 mg/mL. Antithymocyte globulin treatment was contraindicated if erythema larger than 5 mm in diameter, compared with the saline control, developed. Eligible patients were given ATG (Pharmacia, Peapack, New Jersey), 40 mg/kg of body weight daily for 4 days. Antithymocyte globulin was administered intravenously over 4 to 8 hours with oral prednisone, 1 mg/kg daily [minimum of 40 mg/d], for 10 days and then tapered by day 17. Clinic visits were scheduled at 3, 6, and 12 months and then annually. Bone marrow aspirate, biopsy specimens, and bone marrow samples for cytogenetic analysis were obtained at 6 and 12 months and then annually. Excluding transfusions and antibiotics, patients received no other treatment for myelodysplastic syndromes for at least 6 months. The main criterion for response was independence from red blood cell transfusion. This criterion was met if 1) the patient was ...
Phillip Scheinberg, M.D., Olga Nunez, R http://dapoxetineuk.com/side-effects.html .N., B.S.N., Barbara Weinstein, R.N., Priscila Scheinberg, M.S.D., Colin O. Wu, Ph.D., and Neal S. Young, M.D.: Equine versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia Obtained aplastic anemia in the serious form is fatal without treatment.1 Severe aplastic anemia was initially treated with the advancement of stem-cell transplantation in the 1970s definitively. The serendipitous observation of autologous marrow reconstitution in a couple of sufferers with rejected grafts recommended that the conditioning brokers necessary for transplantation might themselves be therapeutic.2 Purposeful immunosuppression induced by the infusion of antithymocyte globulin , polyclonal antibodies generated in pets by inoculation with human thymocytes, became effective, with long-term survival that was similar to the outcomes of stem-cellular transplantation from a histocompatible sibling.3,4 An immune mechanism of ...
A combination of horse anti-thymocyte globulin and cyclosporine produces responses in 60-70% of patients with severe ... a phase II study of rabbit anti-thymocyte globulin and cyclosporine as first-line therapy for severe aplastic anemia. DESIGN AND .... Research Article last updated 10/11/2011 - 5:58pm.. ...
Immunosuppressive therapy is a treatment for aplastic anemia patients who are not candidates for hematopoietic stem cell transplantation. The aim of the study to evaluate the frequency and severity of immunosuppressive therapy-induced hepatotoxicity in patients with aplastic anemia. The records of 27 patients with aplastic anemia who had eceived immunosuppressive therapy were received and determined for evidence of hepatotoxicity. The patients were divided into three groups. Group 1 was treated with antithymocyte/antilymphocyte globulin and cyclosporin A, group 2 received onl yyclosporin-A and group 3 was treated with antithymocyte/antilymphocyte globulin + cyclosporin-A and granulocyte macrophage colony-stimulating factor. All patients in group 1 had an initial increase in AST and ALT levels after therapy, but these tests abnormalities returned to normal in each case (p> 0.05). There was no detectable change in AST and ALT levels in group 2 (p>0.05). In group 3, five patients had an increase in ...
Semantic Scholar extracted view of Fludarabine, cyclophosphamide, and antithymocyte globulin for a patient with dyskeratosis congenita and severe bone marrow failure. by Fabiana Ostronoff et al.
BACKGROUND AND OBJECTIVE: We previously reported that patients with acquired severe aplastic anemia (SAA) treated with antilymphocyte globulin (ALG), 6-methylprednisolone, cyclosporin A (CyA) and granulocyte colony-stimulating factor (G-CSF) can mobilize peripheral blood hemopoietic progenitors (PBHP). The aim of the present study was to assess phenotypic and functional properties of these PBHP. METHODS: We studied seven patients who underwent 43 leukophereses (median 5) between day +30 and +80 following ALG, while in treatment with CyA and G-CSF. Mobilized peripheral blood hemopoietic progenitors were analyzed using surface markers, conventional assays for clonogenic cells (CFU-GM, BFU-E, CFU-GEMM) as well as the recently developed assay for long-term culture initiating cells (LTC-ICs). RESULTS: The proportion of CD34+ cells ranged between 0% and 5.4% (median 0.3%), CD34+DR between 0% and 3.5% (median 0.1%) and CD8+ cells between 3.3% and 56% (median 31%). When light density mononuclear cells ...
BACKGROUND: Surveillance biopsies (SBs) are performed in some pediatric kidney transplant programs, based on data obtained in earlier immunosuppressive eras that the treatment of subclinical acute rejection results in better graft survival. The benefit of SBs for patients on modern immunosuppression regimens is unclear. We have therefore evaluated the clinical utility of SBs in a population of children receiving a kidney transplant. METHODS: We have performed SBs at 3, 6 and 12 months post-transplantation as standard of care at our institution since 2013 in patients on a regimen of rabbit anti-thymocyte globulin, tacrolimus, mycophenolate and rapid steroid taper (RST; steroids maintained in some exceptions ...
Immobilization of Raji cells on surface coated with anti-lymphocyte globulin (ALG) at low cell densities lead to the synthesis of Epstein-Barr virus (EBV) early antigen (EA) in up to 5% of the cells. At higher cell densities the percentage of antigen-positive cells decreased and at confluency no antigen synthesis was observed. Addition of iododeoxyuridine (IdUrd) to low density cultures increased the expression of EA to 20%, whereas in confluent cultures the cells could not be induced to synthesize EA. Treatment of cells in suspension with ALG failed to induced EA synthesis and did not potentiate the effect of IdUrd. Immobilized Raji cells proved to be suitable targets for superinfection with EBV derived from P3HR1 cultures. ...
NFkB p65 Rabbit anti-Human, Mouse, Rat, Polyclonal, eBioscience™ 50 μg; Unconjugated NFkB p65 Rabbit anti-Human, Mouse, Rat, Polyclonal, eBioscience™...
Non-cardiogenic pulmonary edema (NCPE) is a clinical syndrome characterized by simultaneous presence of severe hypoxemia, bilateral alveolar infiltrates on chest radiograph, without evidence of left atrial hypertension/congestive heart failure/fluid
Alemtuzumab to Treat Severe Aplastic Anemia This study is currently recruiting participants. Verified April 2012 by National Institutes of Health Clinical…
Severe aplastic anemia (SAA) is an autoimmune disorder (AID) due to the attack of autoreactive cytotoxic T lymphocytes to the hematopoietic component of the bone marrow.
Severe Aplastic Anemia is a blood disorder where the bodys bone marrow doesnt make enough new blood cells. Learn about the new stem cell treatment option.
In the Subjects, Materials, and Methods Subjects section of this paper one reads: In February 2007, an HIV-infected patient underwent stem cell transplantation (SCT) due to a relapse of AML with a graft consisting of CCR5A32/A32 donor cells. The pre-transplant conditioning regimen included 100 mg/m2 of amsacrine, 30 mg/m2 of fludarabine, 2 g/m2 of cytarabine (day -12 until -9), 60 mg/kg of cyclophosphamide (days -4 and -3), 5.5 mg/kg of rabbit antithymocyte globuline (in three doses between day -3 and -1), and a 400 cGy total body irradiation (TBI; day -5). ART was discontinued on the day of transplantation, and 13 months later the patient received a second transplant with CCR5A32/A32 stem cells from the same donor due to a second relapse of AML. The conditioning regimen consisted of 100 mg/m2 of cytarabine (day -7 until day -1), 6 mg/m2 of gemtuzumab (day -7 and day -1), and a 200 cGy TBI (day -1)... Twelve months post-transplant, the patient underwent liver biopsy and histological examination ...
In the Subjects, Materials, and Methods Subjects section of this paper one reads: In February 2007, an HIV-infected patient underwent stem cell transplantation (SCT) due to a relapse of AML with a graft consisting of CCR5A32/A32 donor cells. The pre-transplant conditioning regimen included 100 mg/m2 of amsacrine, 30 mg/m2 of fludarabine, 2 g/m2 of cytarabine (day -12 until -9), 60 mg/kg of cyclophosphamide (days -4 and -3), 5.5 mg/kg of rabbit antithymocyte globuline (in three doses between day -3 and -1), and a 400 cGy total body irradiation (TBI; day -5). ART was discontinued on the day of transplantation, and 13 months later the patient received a second transplant with CCR5A32/A32 stem cells from the same donor due to a second relapse of AML. The conditioning regimen consisted of 100 mg/m2 of cytarabine (day -7 until day -1), 6 mg/m2 of gemtuzumab (day -7 and day -1), and a 200 cGy TBI (day -1)... Twelve months post-transplant, the patient underwent liver biopsy and histological examination ...
Meteorin Rabbit anti-Human, Polyclonal, Novus Biologicals 0.5mg; Unlabeled Life Sciences:Antibodies:Primary Antibodies:Immunohistochemistry (IHC)
Gentaur molecular products has all kinds of products like :search , Ray Biotech \ Rabbit Anti-Human CD120b \ 129-10094 for more molecular products just contact us
Gentaur molecular products has all kinds of products like :search , Ray Biotech \ Rabbit Anti-Human NALP1 \ 129-10472 for more molecular products just contact us
Interventions: Drug: Cyclophosphamide/Drug: Fludarabine/Drug: Anti-thymocyte globulin/Drug: Cyclosporine A/Drug: Mycophenolate mofetil/Procedure: Hematopoietic stem cell transplant/Procedure: Mesenchymal stem cell transplant/Radiation: Total body ...
A randomized, single-blinded, placebo-controlled trial was performed on 25 subjects: 17 subjects received ATG (2.5 mg/kg intravenously) followed by pegylated G-CSF (6 mg subcutaneously every 2 weeks for 6 doses) and 8 subjects received placebo. The primary outcome was the 1-year change in AUC C-peptide following a 2-hour mixed-meal tolerance test (MMTT). At baseline, the age (mean ± SD) was 24.6 ± 10 years; mean BMI was 25.4 ± 5.2 kg/m2; mean A1c was 6.5% ± 1.1%; insulin use was 0.31 ± 0.22 units/kg/d; and length of diagnosis was 1 ± 0.5 years.. ...
Aplastic anemia is a blood disorder in which the bodys bone marrow doesnt make enough new blood cells. The 3 main types of blood cells your body needs are red blood cells
Y NTEM ve GERE LER: K rk d rt AAA hastas ndaki ve 23 normal kontroldeki CD4+CD25+CD127dim Tregs miktar lar ak sitometrisi kullanarak l ld . Tregs ve T h crelerinin alt tipleri, dentrik h crelerin alt tipleri (DH), gran losit say mlar ve retik losit y zdeleri (%RET) aralar ndaki ili kiler analiz edildi ...
Psychiatry healthcare professionals gain a thorough knowledge base of psychiatric disorder information to offer the best patient care. Get our FREE app now.
Abnormalities of quantities and functions of linker for activations of T cells in severe aplastic anemia.: Our findings demonstrate that dysregulation of LAT ex
THE interaction of lymphocytic choriomeningitis (LCM) virus with mouse tissues has been discussed recently1-5. The fulminating disease, which occurs in adult mice after intracerebral inoculation with LCM virus, can be ameliorated by several treatments known to impair the immune response of the host, such as X-rays6, amethopterin7, thymectomy8 and anti-lymphocyte serum9. The pathology of the disease10 supports the current view that an immune reaction by the host against the virus or a virus product, located in or on infected cells, plays an essential part in its pathogenesis. A similar mechanism may be important in the chronic autoimmune-like disease in virus carrier mice2,5. Further elucidation of this disease mechanism depends on understanding the nature of the immune response and its target. A question of considerable interest is what the consequences might be for virus infected cells in the event of an immune response against the virus or a virus product. Here we report preliminary experiments
Horse anti-human thoracic duct lymphocyte globulin (ATDLG) has been used successfully for the treatment of severe aplastic anemia, although not all lots have comparable efficacy. We have characterized the antibody specificities contained in one lot of Swiss ATDLG found to provide a response rate of 69% and another lot that provided only a 31% response rate. Antibody specificities were analyzed quantitatively by competitive inhibition assays with the use of a panel of fluorescein-conjugated murine monoclonal antibodies that recognize T cell antigens, common leukocyte antigens, and la-like antigens. Although there was wide variation in the amounts of individual antibody specificities within each lot, the effective lot of ATDLG contained an average of 2 1/2 times as much of each antibody specificity as the less effective lot. There were only two antibody specificities that differed remarkably from this pattern; and these deviations did not appear sufficient to account for the variation in ATDLG efficacy.
The ability of preoperative total lymphoid irradiation (TLI) to reduce the need for chronic immunosuppression after cadaveric renal transplantation was examined in 25 recipients who were given a brief course of antithymocyte globulin (ATG) postoperatively with daily low-dose prednisone (0.1-0.2 mg/kg) as the sole maintenance immunosuppressive drug. Patients were selected for the study on the basis of their low levels of cytotoxic antibodies. Grafts were not HLA-matched, and the mean interval between completion of TLI and transplantation was 9 days. During an observation period of up to 25 months, 2 grafts were lost because of rejection. There were two deaths due to disseminated viral infections and two to late cardiovascular complications. At the last observation point, the mean serum creatinine of the 19 patients with functioning grafts was 1.5 mg/dl, and the mean dose of prednisone was 10.2 mg/day. 10 of these patients did not have a rejection episode. Comparison of patients given TLI with a ...
No new relapses seen in single-arm study with new transplant protocol. A myeloablative protocol similar to those used in hematologic malignancies is feasible as a prelude to autologous hemapoietic stem cell transplantation (aHSCT) aimed at halting inflammatory activity in multiple sclerosis, researchers found.. In an uncontrolled study of 24 patients, 70% of those who had near-complete immunoablation with busuflan, cyclophosphamide, and rabbit anti-thymocyte globulin, followed by transplantation of autologous CD34-selected hemapoietic stem cell grafts, met the primary endpoint of activity-free survival at 3 years, according to Harold Atkins, MD, of The Ottawa Hospital, and colleagues.. There were no relapses and no gadolinium-enhancing lesions or new T2 lesions among all the patients who remained in the study, which had up to 13 years of follow up (median 6.7 years), they reported online in The Lancet.. One death occurred in the trial, giving the procedure a mortality rate of 4%, which is ...
VitaDigest offer Hydraplenish Hyaluronic Acid Serum Plus Vitamin C 1 oz Natures Way, Product Review For Natures Way Formula and Information, Exclusive Reivews for Hydraplenish Hyaluronic Acid Serum Plus Vitamin C 1 oz Natures Way Natures Way
... , Rabbit Anti-Human IgG(H+L), Mouse ads-UNLB; N/A; N/A Rabbit Anti-Human IgG (H+L) Absorbed against mouse immunoglobulins
MacSween, RNM and Ono, K and Bell, PRF and Thomason, CM and Starzl, TE (1970) Experimental allergic thyroiditis in rats: suppression by heterologous (rabbit) anti-lymphocyte sera to lymph node, thymic and splenic lymphocytes. Clinical and Experimental Immunology, 6. 273 - 278. ISSN 0009-9104 ...
Rapid responses are electronic letters to the editor. They enable our users to debate issues raised in articles published on thebmj.com. Although a selection of rapid responses will be included online and in print as readers letters, their first appearance online means that they are published articles. If you need the url (web address) of an individual response, perhaps for citation purposes, simply click on the response headline and copy the url from the browser window. Letters are indexed in PubMed ...
Medical information, Acquired aplastic anemia. Definition of Acquired aplastic anemia, symptoms of Acquired aplastic anemia, treatment of Acquired aplastic anemia, and prevention of Acquired aplastic anemia. Exams and Tests Acquired aplastic anemia.
IHCPlus™ APG12 / ATG12 Antibody LS-B2140 is a pathologist validated IHC antibody Rabbit anti-Human APG12 / ATG12. Validated for ELISA,IHC,IP,WB. Tested on 20 paraffin-embedded human tissues.
rabbit, anti-human, igm, ( , chain), f(ab) 2, fragment, affinity, purified, Rabbit anti-Human IgM ( chain), F(ab) 2 Fragment, Affinity purified, AS16 3370
Buy anti-TAC1 antibody, Rabbit anti-Human TAC1 Polyclonal Antibody-CAG46531.1 (MBS6009007) product datasheet at MyBioSource, Primary Antibodies. Application: ELISA (EL/EIA), Western Blot (WB), Flow Cytometry (FC/FACS)
Buy anti-pro-Guanylin, aa4-16 antibody, Rabbit anti-Human pro-Guanylin, aa4-16 Polyclonal Antibody (MBS619595) product datasheet at MyBioSource, Primary Antibodies. Application: ELISA (EL/EIA), Western Blot (WB), Radioimmunoassay (RIA)
Rabbit Anti-Human Gα16 polyclonal antibody.|br| Background: Gα16 is the only hetero-trimeric G protein with a restricted expression pattern in hematopoietic cells. Differentiation of promyelocytic cells leads to decreased expression of Gα16
There are no specific protocols for Rabbit Anti-Human IgG H&L (HRP) preadsorbed (ab98576). Please download our general protocols booklet
PathPlus™ F2RL2 / PAR3 Antibody LS-A261 is a pathologist validated IHC antibody Rabbit anti-Human F2RL2 / PAR3. Validated for ICC,IHC. Tested on 20 paraffin-embedded human tissues.
References for Abcams Rabbit Anti-Human IgG H&L (Biotin) (ab6758). Please let us know if you have used this product in your publication
Rabbit Anti-Human MKK3 Polyclonal Antibody|br| Background: MKK3 is a protein kinase that phosphorylates the p38 MAPK but not ERK MAPK. Phosphorylation by MKK3 occurs on threonine and tyrosine residues and increases the activity of p38 to stimulate transcr
Aplastic Anemia What is aplastic anemia? Aplastic anemia occurs when the bone marrow produces too few of all three types of blood cells: red blood cells, white blood cells, and platelets. A reduced number of red blood cells causes hemoglobin to drop. A reduced number of white blood cells makes the patient susceptible to infection. And, a reduced number of platelets causes the blood not to clot as easily. What causes aplastic anemia? Aplastic anemia has multiple causes. Some of these causes are idiopathi...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
The Aplastic Anemia pipeline report provides detailed information of the Aplastic Anemia pipeline products from the initial phase of product development until its commercialisation in the Aplastic Anemia market.
Aplastic Anaemia Articles: Get information on Aplastic Anaemia. Read articles and learn about all the facts related to Aplastic Anaemia from our health website Onlymyhealth.com.
For those of you whod like a little more in-depth information about what life has been like for David the past 20+ days, heres that update:. Day +22: David had a clinic visit in the hospitals infusion center. At first, he was very uncooperative, and this was hard to handle because hed been doing so well since he was discharged on day +19. It was like as soon as he realized that he was about to step into a hospital room, he stopped in his tracks and wouldnt go in. It took awhile before we finally got him to agree to go into the room and have blood drawn for labs. He also ended up having a dressing and cap change on his PICC line. Overall, Davids labs are good, and hes doing exceptionally well.. *He keeps asking why his hair is gone on an almost daily basis. I explain over and over that its because of the chemotherapy drug, Cytoxan, that his hair has fallen out. I reassure him that it will grow back. David notices that "Caillou is bald," but Im not sure if this makes him feel better or ...
Pain management information for pain medicine healthcare professionals in treating and caring for their patients. Clinical Pain Advisor offers news, case studies and more.
Idiopathic aplastic anemia is a condition in which your bone marrow stops making new blood cells. Learn about the symptoms of aplastic anemia.
Neal Young, MD, discusses the advancement of treatment for aplastic anemia. Young said aplastic anemia used to kill almost all patients diagnosed with the disease within a year.
Definition of aplastic anaemia, with etymology, pronunciation (phonetic and audio), synonyms, antonyms, derived terms and more about the word aplastic anaemia.
Learn more about Aplastic Anemia at Regional Medical Center Bayonet Point DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
Learn more about Aplastic Anemia at Regional Medical Center Bayonet Point DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
100 µg and 30 µg affinity purified rabbit anti-human/mouse/rat BMP-3 polyclonal antibody. Detect mainly the ~16 kDa monomer of BMP-3. Tested in Western Blot.
Two years ago, a doctor used the words cancer and terminal in the same sentence about my husband. My world crashed around me in that minute, and it has yet to rebuild. As a way to cope, I ignored the word terminal. I hoped and prayed that we would find a way for more life. […]. ...
작은, 쉽게 이식할 수 있는 장치는 유럽에서 연구된에 따라 (LVRC) 폐 용적 감소 코일을 기종의 2가지의 모형의 처리에 있는 핵심 역활을, 할 수 있습니다 불렀습니다. 연구 결과의 결과는 장치의 유리한 효력이 처음 처리 후에 년 이상 지속한다는 것을 표시합니다. 연구 결과는 ATS 2013 국제 회의에 제출될 것입니다
This guide provides study problems, suitable for different levels of organic chemistry, all solved and fully explained. Every single step of each problem is shown in a logical and easy-to-follow format, with constant reference to theory. This book provides methods, strategies, and explanations leading students to master organic chemistry problems. This makes it an extremely valuable study support.
A 54 year old woman was referred to our hospital with a diagnosis of very severe aplastic anaemia. She had presented two months previously predominantly with severe thrombocytopenia (haemoglobin (Hb), 10.1 g/litre; white cell count (WCC), 3.2 × 109/litre; neutrophils, 1.7 × 109/litre; platelets, 17 × 109/litre) and had received a course of prednisolone. However, during this period her blood count deteriorated (Hb, 4.7 g/litre; WCC, 3.0 × 109/litre; neutrophils, 0.1 × 109/litre; platelets, 4 × 109/litre) and she was referred for further management. Bone marrow examination revealed a hypocellular marrow consistent with a diagnosis of aplastic anaemia with normal cytogenetics. Investigation failed to reveal the underlying aetiology (hepatitis A, B, and C viruses, Epstein Barr virus, human immunodeficiency virus, and parvovirus were negative and an autoimmune profile, direct Coombs, sucrose lysis, and Hams tests were all normal).. Therefore, the patient was given a five day course of equine ...
TY - JOUR. T1 - Connection between the anti-organ and anti-nuclear titres of antilymphocyte sera and their inhibitory effect on skin graft rejection in mice.. AU - Fekete, B.. AU - Petrányi, G.. AU - Szegedi, G.. AU - Szabó, G.. PY - 1971. Y1 - 1971. UR - http://www.scopus.com/inward/record.url?scp=0015168775&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0015168775&partnerID=8YFLogxK. M3 - Article. C2 - 4948255. AN - SCOPUS:0015168775. VL - 5. SP - 419. EP - 423. JO - Haematologia. JF - Haematologia. SN - 0017-6559. IS - 4. ER - ...
A comparison clinical study of two aplastic anemia treatments found that ATGAM, currently the only licensed aplastic anemia drug in the United States, improved blood cell counts and survival significantly more than did Thymoglobulin, a similar but reportedly more potent treatment. The research was funded by the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health; the study participants were treated and then followed at the NIH Clinical Center in Bethesda, Maryland.. The study will appear in the August 4 New England Journal of Medicine.. "This important study compared the clinical effectiveness of two drugs with similar mechanisms of action. Doctors and patients need to know the most effective therapy for severe aplastic anemia, a rare life-threatening disorder," said Susan Shurin, M.D., acting director of NHLBI.. While Thymoglobulin is not licensed for aplastic anemia in the United States, it has been reported to be effective when used in patients who ...
HRP Conjugated Rabbit Anti-human IgG (gamma-chain specific) secondary antibody This HRP conjugated antibody is specific for human IgG and shows no cross-reactivity with rat/mouse/goat/rabbit IgG.
Shine Serum Plus, one of those multi-functional products, is a clear, light, grease-free formula that colorists use at both the start of their color process (during mixing) and at the finish of their final styling for smoothing shine and thermal styling protection. When added to the color or lightener mixture, Shine Serum Plus creates pure molecular nanotechnology color or lightener. It can be mixed right into the formula of any color manufacturers products to produce an incredible depth of penetration that results in more deep, rich, true-to-color tones and amazingly even color distribution from roots to ends. The product also acts as a buffer to the lightening process, protecting the hair ...
Welcome to All In D! Feel free to submit your top links to our free web directory...Fast approval rate and a large number of categories are just two of the benefits of submitting to us. . Click through any of the categories, or use the search box to find the web site you need ...
My name is Sandra and Im the author of this blog. Im also a Christian, wife, home schooling mom of five, pro blogger, vlogger, and kids YouTube video creator. Its nice to have you here. Read More…. ...
ation 血管重建其它Hemolytic streptococcus 甲族乙型溶血性链球菌Antithymocyte globulin (ATG)抗胸腺细胞球蛋白Vagus nerve 迷走神经,Brainstem death 脑干死亡12Brain death 脑死亡Myocardial remodeling 心肌重塑Hemodynamics 血液动力学Atrial natriuretic f
Objectives: Autologous haematopoietic stem cell transplantation (HSCT) with CD34+ cell selection has recently been used in the treatment of refractory Crohns disease, showing good safety and promising efficacy. We investigated the safety and efficacy of HSCT with unselected peripheral blood stem cells (PBSCs) in moderate-severe refractory Crohns disease.. Patients: Four patients (three male, one female; age range 26-45 years) with active moderate-severe Crohns disease (median Crohns Disease Activity Index (CDAI) 319, range 272-345), refractory or intolerant to multiple drugs including infliximab, were enrolled.. Interventions: Unselected PBSCs were collected after mobilisation with cyclophosphamide (CTX) 1.5 g/m2 and granulocyte-colony stimulating factor (G-CSF) 10 μg/kg. The conditioning regimen included CTX 50 mg/kg on days −5 to −2 and rabbit anti-thymocyte globulin (ATG) 2.5 mg/kg on days −4 to −2.. Main outcome measures: Primary endpoints were toxicity and clinical remission ...
The immunomodulatory potential of cell therapies using adipose-derived stem cells (ASCs) and bone marrow-derived mesenchymal stem cells (BM-MSCs) has been studied in vascularized composite allotransplantation (VCA). Most cell therapy-based experimental and clinical protocols integrate some degree of recipient conditioning/induction with antibodies or other immunosuppressive agents. We investigated the susceptibility of ASCs and BM-MSCs to anti-lymphocyte serum (ALS) and tacrolimus. Rat ASCs and BM-MSCs were exposed to varying concentrations of tacrolimus and ALS in vitro. Serum from ALS-treated animals was added to cell cultures. Viability, susceptibility, and cytotoxicity parameters were evaluated. ALS inhibited ASC and BM-MSC viability and susceptibility in vitro in a dose-dependent manner. ASCs were more susceptible to both ALS and tacrolimus than BM-MSCs. Trypsinized and adherent ASCs were significantly smaller than BM-MSCs. This is the first report on the viability and susceptibility ...
Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia This study is currently recruiting participants. Verified December 2010 by Mayo…
One of the major accomplishments of the first successful lung transplantation in 1963 was the prevention of allograft rejection by using,, and Cobalt-60 irradiation to suppress the recipient immune system. Since then, great progress has been made in
Approaches for haploidentical bone marrow transplantation (BMT) without T-cell depletion have been designed using new transplant strategies, including anti-thymocyte globulin (ATG) preparative regimens, granulocyte colony-stimulating factor-primed grafts, post-transplantation rapamycin, or high-dose cyclophosphamide (Cy) in combination with other immunosuppressive agents for graft-versus-host disease (GVHD) prophylaxis. These strategies ensured fast hematologic engraftment across the human leukocyte antigen (HLA) barrier with an acceptable incidence of GVHD. Long-term follow-up results from different transplant centers suggest that unmanipulated transplantation may provide an alternative strategy in the haploidentical setting without requiring the technical expertise and cost of ex vivo T-cell depletion. This review discusses immune reconstitution and factors associated with clinical outcomes following unmanipulated haploidentical hematopoietic stem cell transplantation (HSCT), and compares ...
Objective: To determine whether high-dose immunosuppressive therapy followed by autologous hematopoietic stem cell transplantation (HDIT/AHSCT) induces sustained remissions and prevents loss of neurologic function in active relapsing-remitting multiple sclerosis (RRMS). Background: HDIT/AHSCT has been assessed as a possible new therapeutic strategy in severe forms of MS. Small uncontrolled studies showed that about 60% to 70% of treated patients do not worsen in the follow-up period of at least 3 years. Responses were best in those with earlier disease stages. Since degenerative changes may contribute to loss of neurologic function in progressive MS, HDIT/AHSCT is being studied in RRMS. Methods: HALT-MS is an ongoing phase 2 clinical trial of HDIT/AHSCT with high-dose chemotherapy (BEAM) and antithymocyte globulin (ATG) in active RRMS (EDSS score, 3.0-5.5; =2 relapses on treatment and EDSS score worsening over past year). This is followed by transplantation with autologous CD34+-selected cells ...

Connection between the anti-organ and anti-nuclear titres of antilymphocyte sera and their inhibitory effect on skin graft...Connection between the anti-organ and anti-nuclear titres of antilymphocyte sera and their inhibitory effect on skin graft...

Fekete B, Petrányi G, Szegedi G, Szabó G. Connection between the anti-organ and anti-nuclear titres of antilymphocyte sera and ... T1 - Connection between the anti-organ and anti-nuclear titres of antilymphocyte sera and their inhibitory effect on skin graft ... Connection between the anti-organ and anti-nuclear titres of antilymphocyte sera and their inhibitory effect on skin graft ... Connection between the anti-organ and anti-nuclear titres of antilymphocyte sera and their inhibitory effect on skin graft ...
more infohttps://hungary.pure.elsevier.com/en/publications/connection-between-the-anti-organ-and-anti-nuclear-titres-of-anti

Reduction in the severity of Mycoplasma pneumoniae-induced pneumonia in hamsters by immunosuppressive treatment with...Reduction in the severity of Mycoplasma pneumoniae-induced pneumonia in hamsters by immunosuppressive treatment with...

Antilymphocyte Serum/therapeutic use*. *Cricetinae. *Histocytochemistry. *Immunity, Cellular. *Injections, Intraperitoneal. * ... in the severity of Mycoplasma pneumoniae-induced pneumonia in hamsters by immunosuppressive treatment with antithymocyte sera. ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/4547395?dopt=Abstract

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch - Full Text View - ClinicalTrials...Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch - Full Text View - ClinicalTrials...

Antilymphocyte Serum. Daclizumab. Immunoglobulin G. Anti-Inflammatory Agents. Antiemetics. Autonomic Agents. Peripheral Nervous ... To achieve serum level of 8-10 ng/ml.. Drug: Dexamethasone 100 mg intra-operatively, and 25 mg every 6h post-operatively for ... To achieve serum level of 8-10 ng/ml.. Drug: Dexamethasone 100 mg intra-operatively, and 25 mg every 6h post-operatively for ...
more infohttps://www.clinicaltrials.gov/ct2/show/NCT00275509

Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease - Full Text View -...Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease - Full Text View -...

Antilymphocyte Serum. Immunosuppressive Agents. Immunologic Factors. Physiological Effects of Drugs. Calcineurin Inhibitors. ... Quantification of serum and urine M protein and serum free light chain analyses for patients with myeloma (Days 35, 70, 100, ... Contraindication to therapy with any one of the proposed agents (e.g., history of allergy to horse serum in ATG). ...
more infohttps://www.clinicaltrials.gov/ct2/show/NCT02158052?term=%22bone+marrow%22&recrs=ab&rank=33

Cord Blood Expansion on Mesenchymal Stem Cells - Full Text View - ClinicalTrials.govCord Blood Expansion on Mesenchymal Stem Cells - Full Text View - ClinicalTrials.gov

Antilymphocyte Serum. Rituximab. Fludarabine. Clofarabine. Mycophenolic Acid. Vidarabine. Immunosuppressive Agents. Immunologic ... Serum glutamate pyruvate transaminase (SGPT)/bilirubin , / = to 2.0 x normal (Myeloablative Regimen 4, Reduced Intensity ...
more infohttps://clinicaltrials.gov/ct2/show/study/NCT00498316?view=results

Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation in Aplastic Anemia - Full Text View - ClinicalTrials.govFludarabine-Based Conditioning for Allogeneic Marrow Transplantation in Aplastic Anemia - Full Text View - ClinicalTrials.gov

Antilymphocyte Serum. Fludarabine. Vidarabine. Immunosuppressive Agents. Immunologic Factors. Physiological Effects of Drugs. ... serum total bilirubin , 2x upper limit of normal for age as per local laboratory; ALT and AST , 4x upper limit of normal for ... age as per local laboratory; c) renal: serum creatinine , 2x upper limit of normal for age (as per local laboratory). d) ...
more infohttps://clinicaltrials.gov/ct2/show/NCT00474747?recr=Open&cond=%22Anemia%2C+Aplastic%22&rank=11

Effect of length of gestation on maternal cellular immunity to human trophoblast antigens.Effect of length of gestation on maternal cellular immunity to human trophoblast antigens.

Antilymphocyte Serum. Cytotoxicity Tests, Immunologic. Female. Gestational Age*. Humans. Immunity, Cellular*. Lymphocytes / ... 8906258 - Activated cellular immunity and decreased serum tryptophan in healthy pregnancy.. 7312228 - Acceleration of fetal ...
more infohttp://www.biomedsearch.com/nih/Effect-length-gestation-maternal-cellular/984088.html

All out | definition of all out by Medical dictionaryAll out | definition of all out by Medical dictionary

2. antilymphocyte serum. ALL. 1 abbreviation for acute lymphocytic leukemia. 2 abbreviation for acute lymphoid leukemia. ...
more infohttps://medical-dictionary.thefreedictionary.com/all+out

Serums | definition of serums by Medical dictionarySerums | definition of serums by Medical dictionary

... serums explanation free. What is serums? Meaning of serums medical term. What does serums mean? ... Looking for online definition of serums in the Medical Dictionary? ... See Acute phase serum, Antilymphocyte serum, Convalescent serum.. se·rum. , pl. sera, pl. serums (sērŭm, -ă, -ŭmz ) 1. A clear ... serum. (redirected from serums). Also found in: Dictionary, Thesaurus, Encyclopedia. serum. [se´rum] (pl. serums, se´ra) (L.) ...
more infohttp://medical-dictionary.thefreedictionary.com/serums

Prophylactic Use of Rabbit Antihuman Thymocyte Immunoglobulin in Renal TransplantationProphylactic Use of Rabbit Antihuman Thymocyte Immunoglobulin in Renal Transplantation

ATG is a polyclonal antilymphocyte serum. It contains specific antibodies that act directly against a variety of T cell surface ... serum level of creatinine elevated by more than 15%; (3) increased urinary protein; (4) color Doppler ultrasound indicating an ...
more infohttps://www.urotoday.com/volume-3-2010/vol-3-issue-6/39453-prophylactic-use-of-rabbit-antihuman-thymocyte-immunoglobulin-in-renal-transplantation-2232373.html

The spontaneous and induced synthesis of Epstein-Barr virus antigens in Raji cells immobilized on surface coated with anti...The spontaneous and induced synthesis of Epstein-Barr virus antigens in Raji cells immobilized on surface coated with anti...

Antilymphocyte Serum/pharmacology. MESH. Cells, Cultured. MESH. Herpesvirus 4, Human/immunology. MESH. ... Immobilization of Raji cells on surface coated with anti-lymphocyte globulin (ALG) at low cell densities lead to the synthesis ... Immobilization of Raji cells on surface coated with anti-lymphocyte globulin (ALG) at low cell densities lead to the synthesis ... The spontaneous and induced synthesis of Epstein-Barr virus antigens in Raji cells immobilized on surface coated with anti-lymphocyte ...
more infohttps://epub.uni-regensburg.de/20710/

Chicago Drugstore: Discount viagra from canada original suppliers!Chicago Drugstore: Discount viagra from canada original suppliers!

In antilymphocyte serum was introduced. If consent for organ retrieval and rewarming that occurs naturally in the proximal ... Janssen-cilag, pp Serum ferritin levels should be observed closely for any one of the pronephric primordium lim related genes ... capd involves the normalisation of serum levels for the patient is shivering hyperthermic or a definitive diagnosis can be ...
more infohttp://www.nationalnewstoday.com/medical/discount-viagra-from-canada/2/

Online Drugstore: Dosage for metronidazole er for human beings 10% discount!Online Drugstore: Dosage for metronidazole er for human beings 10% discount!

The antilymphocyte serum was introduced. Some centers will reuse the blood normally in wnt deficient female mice at and hours ... And encouraging patients to adhere to undamaged endothelial tissue, the nurse practitioner is able to increase serum calcium ... Avia measurement of serum potassium levels for urea distribution total body water on average due to bacterial colonisation of ...
more infohttp://www.nationalnewstoday.com/medical/dosage-for-metronidazole-er-for-human-beings/2/

Aplastic Anemia Differential DiagnosesAplastic Anemia Differential Diagnoses

Re-treatment of aplastic anemia with antithymocyte globulin or antilymphocyte serum. Am J Med. 1988 Apr. 84(4):678-82. [Medline ... Treatment of aplastic anemia with an investigational antilymphocyte serum prepared in rabbits. Am J Med Sci. 1994 Dec. 308(6): ... Liu H, Mihara K, Kimura A, Tanaka K, Kamada N. Induction of apoptosis in CD34+ cells by sera from patients with aplastic anemia ... Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood. 1987 Oct. 70(4):1046-52 ...
more infohttps://emedicine.medscape.com/article/198759-differential

Aplastic Anemia: Practice Essentials, Background, EtiologyAplastic Anemia: Practice Essentials, Background, Etiology

Re-treatment of aplastic anemia with antithymocyte globulin or antilymphocyte serum. Am J Med. 1988 Apr. 84(4):678-82. [Medline ... Treatment of aplastic anemia with an investigational antilymphocyte serum prepared in rabbits. Am J Med Sci. 1994 Dec. 308(6): ... Liu H, Mihara K, Kimura A, Tanaka K, Kamada N. Induction of apoptosis in CD34+ cells by sera from patients with aplastic anemia ... Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood. 1987 Oct. 70(4):1046-52 ...
more infohttps://emedicine.medscape.com/article/198759-overview

Peroxisomal Acyl-Coa Oxidase Deficiency disease: Malacards - Research Articles, Drugs, Genes, Clinical TrialsPeroxisomal Acyl-Coa Oxidase Deficiency disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Antilymphocyte Serum. Phase 2. 12. Antimetabolites. Phase 2. 13. Antimetabolites, Antineoplastic. Phase 2. ... normal serum plasmalogen increased plasma levels of very-long chain fatty acids (vlcfa) decreased or absent peroxisome acyl-coa ... straight-chain acyl-coa oxidase.diagnostic methodsdiagnosis is based on laboratory studies revealing increased serum very-long ...
more infohttp://www.malacards.org/card/peroxisomal_acyl_coa_oxidase_deficiency

Transplant - Special legal and ethical problems | Britannica.comTransplant - Special legal and ethical problems | Britannica.com

The activity of the antilymphocyte serum lies in its gamma globulin, which contains the antibody proteins. Antilymphocyte ... Such antilymphocyte serums can be produced between a variety of species, but in higher mammals, particularly humans, it has ... The horse has usually been used to produce antilymphocyte serum for the treatment of human patients, but some persons are ... If the lymphocytes of both the recipient and the potential donor are killed by a given serum, then, as far as that typing serum ...
more infohttps://www.britannica.com/science/transplant-surgery/Special-legal-and-ethical-problems

Irene Lorand-Metzes Research on Refractory Anemia with Excess of Blasts (RAEM)
     | CureHunterIrene Lorand-Metze's Research on Refractory Anemia with Excess of Blasts (RAEM) | CureHunter

Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 04/2006. 1. Granulocyte Colony-Stimulating Factor (G-CSF)IBA 04/2006. ...
more infohttp://www.curehunter.com/public/authorSummary-Lorand-Metze,%20Irene.do?keywordId=D000754

Self-Tolerance Checkpoints in CD4 T Cells Specific for a Peptide Derived from the B Cell Antigen Receptor | The Journal of...Self-Tolerance Checkpoints in CD4 T Cells Specific for a Peptide Derived from the B Cell Antigen Receptor | The Journal of...

V. Use of antilymphocyte serum to deplete animals of helper cells. Eur. J. Immunol. 1: 68-75. ... Quantifying serum Ig. To quantify serum IgG and IgM, 96-well trays were coated overnight at 4°C with 1 μg/ml of H chain- ... C, Mean total κTg Ig concentrations in sera of mixed chimeras. κTg-F1 denotes pooled sera of three κTg mice. *, undetectable. D ... 2D, the low levels of κTg serum Ig in mixed chimeras were not a consequence of a reduced quantity of total Ig, as mg/ml ...
more infohttp://www.jimmunol.org/content/187/1/82

HLA-haploidentical Allogeneic Hematopoietic Cell Transplantation Using CD3±CD19 Depletion for Patients With Aplastic Anemia...HLA-haploidentical Allogeneic Hematopoietic Cell Transplantation Using CD3±CD19 Depletion for Patients With Aplastic Anemia...

Rationale: Chemotherapy with fludarabine, cyclophosphamide and anti-thymocyte globulin may induce the engraftment cross the immunologic barrier in the setting of HLA-haploidentical allogeneic hematopoietic cell transplantation. In addition, depletion CD3±CD19 cells may contribute to prevent developing severe acute graft versus host disease (GVHD) in haploidentical transplantation. Purpose: This phase I/II trial is to evaluate the safety and efficacy of fludarabine, cyclophosphamide and antithymocyte globulin with CD3±CD19 depleted graft from haploidentical donors in treating patients with aplastic anemia.
more infohttps://ichgcp.net/clinical-trials-registry/NCT01105273

Treatment with polyclonal antilymphocyte globulins indu | Open-iTreatment with polyclonal antilymphocyte globulins indu | Open-i

Treatment with polyclonal antilymphocyte globulins induces depletion of circulating CD3+CD4+CD28− T-cells in transplant ... Antilymphocyte Serum/immunology/pharmacology*. *Apoptosis/drug effects*/immunology. *CD4-Positive T-Lymphocytes/drug effects*/ ... pone-0033939-g001: Treatment with polyclonal antilymphocyte globulins induces depletion of circulating CD3+CD4+CD28− T-cells in ... pone-0033939-g001: Treatment with polyclonal antilymphocyte globulins induces depletion of circulating CD3+CD4+CD28− T-cells in ...
more infohttps://openi.nlm.nih.gov/detailedresult.php?img=PMC3316508_pone.0033939.g001&req=4
  • Liu H, Mihara K, Kimura A, Tanaka K, Kamada N. Induction of apoptosis in CD34+ cells by sera from patients with aplastic anemia. (medscape.com)
  • However, these studies were performed in mice with nearly monoclonal populations of B and T cells and with high concentrations of serum mAb bearing antigenic V region peptides ( 14 , 18 , 19 ). (jimmunol.org)
  • In this way, Johan van Dongen noticed that Aids can be induced by radiation, aflatoxins, Immuran/prednisolone combination, anti-lymphocyte sera and many other bio-warfare agents. (wordpress.com)
  • The institute became even better known world wide because of the anti lymphocyte serum which was an effective treatment to suppress organ rejection and led to a cooperation with Prof. Barnard in the early heart transplantations. (uni-muenchen.de)
  • Tacrolimus pharmacokinetics following a single IV administration were determined in 12 patients (7 not on dialysis and 5 on dialysis, serum creatinine of 3.9±1.6 and 12.0±2.4 mg/dL, respectively) prior to their kidney transplant. (medlibrary.org)
  • Chez les patients épileptiques ou ayant des antécédents d'épilepsie, il est prudent de renforcer la surveillance clinique et électrique, en raison de la possibilité d'abaissement du seuil épileptogène? (doughertyrealestate.net)